Molecular basis of immune evasion strategies by adenoviruses

Immunology and Cell Biology

Volumn 74, Issue 6, 1996, Pages 504-512

  Hayder, Hikmat ^a   Müllbacher, Arno ^a  

^a Biology and Environment   (Australia)

Author keywords

adenovirus; host defence; immune evasion; viral pathogenesis

Indexed keywords

CYTOKINE; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR;

ADENOVIRUS; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; GENE EXPRESSION; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; REVIEW; VIRUS INFECTION;

ADENOVIRIDAE; HUMAN ADENOVIRUS;

EID: 0029774441     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1996.83     Document Type: Review

References (138)

1. Gooding LR. Virus proteins that counteract host immune defences. Cell 1992; 71: 5-7.
2. Hierholzer JC, Stone YO, Broderson JR. Antigenic relationships among the 47 human adenoviruses determined in horse reference antisera. Arch. Virol 1991; 121: 179-97.
3. Schnurr D, Dondero ME. Two new candidate adenovirus serotypes. Intervirology 1993; 36: 79-83.
4. Green M, Mackey JK, Wold WSM, Ridgen P. Thirty-one human adenovirus serotypes (Ad1-31) form five groups (A-E) based upon DNA genome homologies. Virology 1979; 93: 481-92.
5. Wadell G, Allard A, Evander M, Li QC. Genetic variability and evolution of adenoviruses. Chem. Scr. 1986; 26B: 325-35.
6. Horwitz MS. Adenoviruses. In: Fields BN, Knipe DM, eds. Virology, 2nd edn. New York: Raven Press Ltd, 1990; 1723-40.
7. Fox JP, Hall CE, Cooney MK. The Seattle virus watch. Am. J. Epidemiol. 1977; 105: 362-86.
8. Neumann R, Genersch E, Eggers HJ. Detection of adenovirus nucleic acid sequences in human tonsils in the absence of infectious virus. Virus Res. 1987; 7: 93-7.
9. Zahradnik JM, Spencer MJ, Parker DD. Adenovirus infection in the immunocompromised patient. Am. J. Med. 1980; 68: 725-32.
10. Hierholzer JC. Adenoviruses in the immunocompromised host. Clin. Microbiol. Rev. 1992; 5: 262-74.
11. Stephens C, Harlow E. Differential splicing yields novel adenovirus 5 E1A mRNAs that encode 30kd and 35kd proteins. EMBO J. 1987; 6: 2027-35.
12. Van Ormondt H, Maat J, Dijkema R. Comparison of nucleotide sequences of the early E1a regions for subgroups A, B, and C of human adenoviruses. Gene 1980; 12: 63-76.
13. Ruley HE. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 1983; 304: 602-6.
14. Moran E, Mathews MB. Multiple functional domains in the adenovirus E1A gene. Cell 1987; 48: 177-8.
15. Lillie JW, Lowenstein PM, Green MR, Green M. Functional domains of adenovirus type 5 E1a proteins. Cell 1987; 50: 1091-100.
16. Rao L, Debbas M, Sabbatini P, Hockenberry D, Korsmeyer S, White E. The adenovirus E1A proteins induce apoptosis which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc. Natl Acad. Sci. USA 1992; 89: 7742-6.
17. Lowe SW, Ruley HE. Stabilization of the P53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Gene Dev. 1993; 7: 535-45.
18. Duerksen-Hughes PJ, Wold WSM, Gooding LR. Adenovirus E1A renders infected cells sensitive to cytalysis by tumor necrosis factor. J. Immunol. 1989; 143: 4193-200.
19. Bellgrau D, Walker TA, Cook J. Recognition of adenovirus E1A gene products on immortalized cell surfaces by cytotoxic T lymphocytes. J. Virol. 1988; 62: 1513-19.
20. Müllbacher A, Bellet AJD, Tha Hla R. The murine cellular immune response to adenovirus type 5. Immunol. Cell Biol. 1989; 67: 31-9.
21. Cladaras C, Bhat B, Wold WSM. Mapping the 5′ ends, 5′ ends and splice sites of mRNA from the early E3 transcription unit of adenovirus 5. Virology 1985; 140: 44-54.
22. Wold WSM, Gooding LR. Region E3 of adenovirus: a casette of genes involved in host immunosurveillance and virus-cell inter actions. Virology 1991; 184: 1-8.
23. Jones N, Shenk T. Isolation of deletion and substitution mutants of adenovirus type 5. Cell 1978; 13: 181-8.
24. Groff DE, Daniell E. Isolation and characterization of a viable deletion mutant of adenovirus type 3. Virology 1980; 106: 191-4.
25. Müllbacher A. Viral escape from immune recognition: multiple strategies of adenovirus. Immunol. Cell Biol. 1992; 70: 59-63.
26. Wold WSM, Tollefson AE, Hermiston TW. Strategies of immune modulation by adenovirus. In: McFadden G, ed. Viroceptors, Virokines and Related Immune Modulators Encoded by DNA Virus. Austin: RG Landes Company, 1995; 147-85.
27. Staeheli P. Interferon induced proteins and the antiviral state. Adv. Virus Res. 1990; 38: 147-201.
28. Samuel CE. Antiviral actions of interferon: interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 1991; 183: 1-11.
29. Sen GC, Ramsohoff RM. Interferon induced antiviral actions and their regulation. Adv. Virus Res. 1993; 42: 57-102.
30. Hovanessian A. The double-stranded RNA-activated protein kinase induced by interferon: dsRNA-PK. J. Interferon Res. 1989; 9: 641-7.
31. I. Virology 1988; 164: 106-13.
32. Mathews M, Shenk T. Adenovirus virus-associated RNA and translation control. J. Virol. 1991; 65: 5657-62.
33. Samuel CE. Mechanisms of the antiviral action of interferon. Prog. Nucleic Acid Res. Mol. Biol. 1988; 35: 27-72.
34. r protein kinase to regulate its autophosphorylation and activity. EMBO J. 1987; 6: 689-97.
35. Ghadge GD, Swaminathan S, Katze MG, Thimmapaya B. Binding of the adenovirus V1RNA to the interferon induced 68-kDa protein kinaze correlates with function. Proc. Natl Acad. Sci. USA 1991; 88: 7140-4.
36. Clarke PA, Schwemmle M, Schickinger J, Hilse K, Clemens M. Binding of Epstein-Barr virus small RNA EBER-1 to the double-stranded RNA-activated protein kinase DAI. Nucleic Acid Res. 1991; 19: 243-8.
37. Akkaraju GR, Whitaker-Dowling P, Youngner JS, Jagus R. Vaccinia-specific kinase inhibitory factor prevents translational inhibition by double-stranded RNA in rabbit reticulocyte lysate. J. Biol. Chem. 1989; 264: 1321-5.
38. Beattie E, Tartaglia J, Paoletti E. Vaccinia virus-encoded eIF-2 alpha homology abrogates the antiviral effect of interferon. Virology 1991; 183: 419-22.
39. Anderson KP, Fennie EH. Adenovirus early region 1A modulation of interferon antiviral activity. J. Virol. 1987; 61: 787-95.
40. Reich N, Pine R, Levy D, Darnell JE Jr. Transcription of Interferon-stimulated genes is induced by adenovirus particles but is suppressed by E1A gene products. J. Virol. 1988; 62: 114-9.
41. Ackrill AM, Foster GR, Laxton CD, Flavell DM, Stark GR, Kerr IM. Inhibition of the cellular response to interferons by products of the adenovirus type 5 E1 oncogene. Nucleic Acid Res. 1991; 19: 4387-93.
42. Gutch MJ, Reich NC. Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene. Proc. Natl Acad. Sci. USA 1991; 88: 7913-17.
43. Kalvakolanu D, Bankyopadhyay S, Harter M, Sen G. Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation. Proc. Natl Acad. Sci. USA 1991; 88: 7459-63.
44. Pellegrini S, Schindler C. Early events in signalling by interferons. TIBS 1993; 18: 338-42.
45. Hunter T. Cytokine connections. Nature 1993; 366: 114-16.
46. Schindler C, Shuai K, Prezioso VR, Darnell JE Jr. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 1992; 257: 809-13.
47. Fu X-Y. A transcription factor with SH2 and SH3 domains is directly activated by an interferon α-induced cytoplasmic protein tyrosine kinase(s). Cell 1992; 70: 323-35.
48. Kessler DS, Veals SA, Fu X-Y, Levy DE. Interferon-alpha regulates nuclear translocation and DNA binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev. 1990; 4: 1753-65.
49. Decker T, Lew DJ, Darnell JE Jr. Two distinct alpha-interferon-dependent signal transduction pathways may contribute to activation of transcription of the guanylate-binding protein gene. Mol. Cell. Biol. 1991; 10: 927-32.
50. Shuai K, Schindler C, Prezioso VR, Darnell JE Jr. Activation of transcription by IFN-γ: tyrosine phosphorylation of a 91kD DNA binding protein. Science 1992; 258: 1808-12.
51. Routes JM, Li H, Bayley ST, Ryan S, Klemm DJ. Inhibition of IFN-stimulated gene expression and IFN induction of a cytolytic resistance to natural killer cell lysis correlate with E1A-P300. J. Immunol. 1996; 156: 1055-61.
52. Arany Z, Newsome D, Oldread E, Livingston DM, Eckner R. A family of transcriptional adaptor proteins targeted by the E1A protein. Nature 1995; 374: 81-4.
53. Routes JM. Adenovirus E1A inhibits IFN-induced resistance to cytolysis by natural killer cells. J. Immunol. 1993; 150: 4315-22.
54. Van Snick J. Interleukin-6: an overview. Annu. Rev. Immunol. 1990; 8: 253-78.
55. Hirano T. The biology of interleukin-6. Chem. Immunol. 1992; 51: 153-6.
56. Janaswami PM, Kalvakolanu DVR, Zhang Y, Sen GC. Transcriptional repression of interleukin-6 gene by adenoviral E1A proteins. J. Biol. Chem. 1992; 267: 24 886-91.
57. Takeda T, Nakajima K, Kojima H, Hirano T. E1A repression of IL-6-induced gene activation by blocking the assembly of IL-6 response element binding complexes. J. Immunol. 1994; 153: 4573-82.
58. Sadowski HB, Shuai K, Darnell Jr JE, Gilman MZ. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 1993; 261: 739-42.
59. Zhong Z, Wen Z, Darnell J Jr. Stat 3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264: 95-8.
60. Vassali P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 1992; 10: 411-52.
61. 2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation. Cell 1986; 45: 659-66.
62. Mestan J, Digel W, Mittnacht S et al. Antiviral effects of recombinant tumour necrosis factor in vitro. Nature 1986; 323: 816-19.
63. Wong GHW, Goeddel DV. Tumour necrosis factors α and β inhibit virus replication and synergize with interferons. Nature 1986; 323: 819-22.
64. Kirstein M, Baglioni C. Tumor necrosis factor induces synthesis of two proteins in human fibroblasts. J. Biol. Chem. 1986; 261: 9565-76.
65. Hayakawa M, Ishida N, Takeuchi K et al. Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cytotoxic action of tumor necrosis factor. J. Biol. Chem. 1993; 268: 11 290-5.
66. 2+-dependent translocation domain with homology to PKC and GAP. Cell 1991; 65: 1043-51.
67. Knauer MF, Longmuir KJ, Yamamoto RS, Fitzgerald TP, Granger GA. A mechanism of human lymphotoxin and tumor necrosis factor induced destruction of cells in vitro: phospholipase activation and deacylation of specific-membrane phospholipids. J. Cell Physiol. 1990; 142: 469-79.
68. Chen MJ, Holskin B, Strickler J et al. Induction of E1A oncogene expression of cellular susceptibility to lysis by TNF. Nature 1987; 330: 581-4.
69. Ames RS, Holskin B, Mitcho M, Shalloway D, Chen MJ. Induction of sensitivity to the cytotoxic action of tumor necrosis factor alpha byadenovirus E1A is independent of transformation and transcriptional activation. J. Virol. 1990; 64: 4115-22.
70. Duerksen-Hughes P, Hermiston TW, Wold WSM, Gooding LR. The amino terminal portion of CD1 of the adenovirus E1A protein is required to induce susceptibility to tumor necrosis factor cytolysis in adenovirus-infected mouse cells. J. Virol. 1991; 65: 1236-44.
71. Bayley ST, Mymryk JS. Adenovirus E1A proteins and transformation. Int. J. Oncol. 1994; 5: 425-44.
72. Shisler J, Duerksen-Hughes P, Hermiston T, Wold WMS, Gooding LR. Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. J. Virol. 1996; 70: 68-77.
73. Hamel PA, Phillips RA, Muncaster M, Gallie BL. Speculation on the roles of RBL in tissue-specific differentiation, tumor initiation and tumor progression. FASEB J. 1993; 7: 846-54.
74. Eckner R, Ewen ME, Newsome D et al. Molecular cloning and functional analysis of adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 1994; 8: 869-84.
75. Gooding LR, Elmore LW, Tollefson AE, Brady HA, Wold WS. A 14 700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell 1988; 53: 341-6.
76. Gooding LR, Ranheim TS, Tollefson AE et al. The 10 400 and 14 500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor. J. Virol. 1991; 65: 4114-23.
77. Gooding LR. Regulation of TNF-mediated cell death and inflammation by human adenoviruses. Infect. Agents Dis. 1994; 3: 106-15.
78. Persson H, Signas C, Phillipson L. Purification and characterization of an early glycoprotein from adenovirus from type 2-infected cells. J. Virol. 1979; 29: 938-48.
79. Gooding LR, Sofola IO, Tollefson AE, Duerksen-Hughes P, Wold WS. The adenovirus E3-14.7K protein is a general inhibitor of tumor necrosis factor-mediated cytolysis. J. Immunol. 1990; 145: 3080-6.
80. Hoffman P, Yaffe MB, Hoffman BL, Yei S, Wold WS, Carlin C. Characterization of the adenovirus E3 protein that down-regulates the epidermal growth factor receptor. J. Biol. Chem. 1992; 267: 13480-7.
81. Carlin CR, Tollefson AE, Brady HA, Hoffman BL, Wold WS. Epidermal growth factor receptor is downregulated by a 10 400 MW protein encoded by the E3 region of adenovirus. Cell 1989; 57: 135-44.
82. Tollefson AE, Stewart AR, Yei S, Saha SK, Wold WSM. The 10 400-and 14 500-dalton protein encoded by region E3 of adenovirus form a complex and function together to downregulate the epidermal growth factor receptor. J. Virol. 1991; 65: 3095-105.
83. 2 is coupled to hormonally regulated release of arachidonic acid. Proc. Natl Acad. Sci. USA 1992; 89: 6147-51.
84. Zhang X, Bellett AJD, Tha Hla R, Voss T, Müllbacher A, Braith waite A. Down-regulation of human adenovirus E1a by E3 gene products: evidence for translational control of E1a by E3 14.5K and/or E3 10.4K products. J. Gen. Virol. 1994; 75: 1943-51.
85. White E, Sabbatini P, Debbas M, Wold WS, Kusher DI, Gooding LR. The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor alpha. Mol. Cell. Biol. 1992; 12: 2570-80.
86. White E, Blose SH, Stillman B. Nuclear envelope localization of an adenovirus tumor antigen maintains the integrity of cellular DNA. Mol. Cell. Biol. 1984; 4: 2865-75.
87. White E, Cipriani R. Specific disruption of intermediate filaments and the nuclear lamina by the 19-kDa product of the adenovirus E1B oncogene. Proc. Natl Acad. Sci. USA 1989; 86: 9886-90.
88. Tufariello J, Cho S, Horwitz MS. The adenovirus E3 14.7-kilodalton protein which inhibits cytolysis by tumor necrosis factor increases the virulence of vaccinia virus in a murine pneumonia model. J. Virol. 1994; 68: 453-62.
89. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc. Natl Acad. Sci. USA 1992; 89: 7742-6.
90. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 1992; 357: 82-5.
91. Subramanian T, Kuppuswamy M, Gysbers J, Mak S, Chinnadurai G. 19 kDa tumor antigen coded by early region E1b of adenovirus 2 is required for efficient synthesis and for protection of viral DNA. J. Biol. Chem. 1984; 259: 11 777-83.
92. White E, Grodzicker T, Stillman BW. Mutations of the gene encoding the adenovirus early region 1B 19 000-molecular-weight tumor antigen cause the degradation of chromosomal DNA. J. Virol. 1984; 52: 410-19.
93. Farrow SN, White JHM, Martinou I et al. Cloning of a Bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 1995; 374: 731-3.
94. Chittenden T, Harrington EA, O'Connor R et al. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995; 374: 733-6.
95. Kiefer MC, Brauer MJ, Powers VC et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995; 374: 736-9.
96. White E. Death-defying acts: a meeting review on apoptosis. Genes Dev. 1993; 7: 2277-84.
97. Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu. Rev. Immunol. 1989; 7: 601-24.
98. Berke G. The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu. Rev. Immunol. 1994; 12: 735-73.
99. Bjorkman PJ, Parham P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu. Rev. Biochem. 1990; 59: 253-72.
100. Müllbacher A, Ebnet K, Blanden RV et al. Granzyme A is critical for recovery of mice from infection with the natural cytopathic viral pathogen, ectromelia. Proc. Natl Acad. Sci. USA 1996; 93: 5783-7.
101. Kvist S, Ostberg L, Pesson H, Philipson L, Peterson PA. Molecular association between transplantation antigens and cell surface antigen in adenovirus-transformed cell line. Proc. Natl Acad. Sci. USA 1978; 75: 5674-8.
102. Paabo S, Bhat BM, Wold WSM, Peterson PA. A short sequence in the COOH-terminus makes an adenovirus membrane glycoprotein a resident of the endoplasmic reticulum. Cell 1987; 50: 311-17.
103. Nilsson T, Jackson M, Peterson PA. Short cytoplasmic sequences serve as retention signals for transmembrane proteins in the endoplasmic reticulum. EMBO J. 1990; 9: 3153-62.
104. Jackson MR, Nilsson T, Peterson PA. Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum. EMBO J. 1990; 9: 3153-62.
105. Cox JH, Bemmink JR, Yewdell JW. Retention of adenovirus E19 glycoprotein in the endoplasmic reticulum is essential to its ability to block antigen presentation. J. Exp. Med. 1991; 174: 1629-37.
106. Burgert H-G, Kvist S. The E3/19K protein of adenovirus type 2 binds to the domains of histocompatibility antigens required for CTL recognition. EMBO J. 1987; 6: 2019-26.
107. Jeffries WA, Burgert H-G. E3/19K form adenovirus 2 is an immunosubversive protein that binds to a structural motif regulating the intracellular transport of major histocompatibility complex class I proteins. J. Exp. Med. 1990; 172: 1653-64.
108. Feuerbach D, Etteldorf S, Ebenau-Jehle C, Abastado JP, Madden D, Burgert HG. Identification of amino acids within the MHC molecule important for the interaction with the adenovirus protein E3/19K. J. Immunol. 1994; 153: 1626-36.
109. Pääbo S, Weber F, Nilsson T, Schaffner W, Peterson PA. Structural and functional dissection of an MHC class 1 antigen-binding adenovirus glycoprotein. EMBO J. 1986; 5: 1921-7.
110. Sester M, Burgert H-G. Conserved cysteine residues within the E3/19K protein of adenovirus type 2 are essential for binding to major histocompatibility complex antigens. J. Virol. 1994; 68: 5423-32.
111. Burgert H-G, Kvist S. An adeno virus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 1985; 41: 987-97.
112. Andersson M, Pääbo T, Nilsson T, Peterson PA. Impaired intracellular transport of class I MHC antigens as a possible means of adenoviruses to evade immune surveillance. Cell 1985; 43: 215-22.
113. Beier DC, Cox JH, Vining DR, Cresswell P, Engelhard VH. Association of human class I MHC alleles with adenovirus E3/19K protein. J. Immunol. 1994; 152: 3862-72.
114. b-restricted SV40-specific CTL-mediated lysis. Virology 1988; 165: 357-66.
115. Flomenberg P, Szmulewicz J, Gutierrez E, Lupatkin H. Role of the adenovirus E3-19K conserved region in binding major histocompatibility complex class I molecules. J. Virol. 1992; 66: 4778-83.
116. Burgert H-G, Maryanski JL, Kvist S. 'E3/19K' protein adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens. Proc. Natl Acad. Sci. USA 1987; 84: 1356-60.
117. Ginsberg HS, Lundholm-Beauchamp U, Horswood RL et al. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc. Natl Acad. Sci. USA 1989; 86: 3823-7.
118. Rawle FC, Tollefson AE, Wold WSM, Gooding LR. Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp 19K but not E3 14.7K. J. Immunol. 1989; 143: 2031-7.
119. Cox JH, Yewdell JW, Eisenlohr LC, Johnson PR, Benning JR. Antigen presentation requires transport of MHC class 1 molecules from the endoplasmic reticulum. Science 1990; 247: 715-18.
120. Korner H, Fritzsche U, Burgert H-G. Tumor necrosis factor a stimulates expression of adenovirus early region 3 proteins: Implications for viral persistence. Proc. Natl Acad. Sci. USA 1992; 89: 11 857-61.
121. Cox JH, Buller RML, Bennink JR, Yewdell JW, Karupiah G. Expression of adenovirus E3/19K protein does not alter mouse MHC class I-restricted response to vaccinia virus. Virology 1994; 204: 558-62.
122. Sliver L, Anderson CW. Interaction of human adenovirus serotype 2 with a human lymphoid cells. Virology 1988; 165: 377-87.
123. Horvath J, Palkonyay L, Weber J. Group C adenovirus DNA sequences in human lymphoid cells. J. Virol. 1986; 59: 189-92.
124. Horvath J, Weber JM. Nonpermissivity of human peripheral blood lymphocytes to adenovirus type 2. J. Virol. 1988; 62: 341-5.
125. Korner H, Burgert H-G. Down-regulation of HLA antigens by the adenovirus type 2 E3/19K protein in a T-lymphoma cell line. J. Virol. 1994; 68: 14 442-8.
126. Schrier PI, Bernards R, Vaessen RTMJ, Houweling A, Van der Eb AJ. Expression of class 1 major histocompatibility antigens switched off by highly oncogenic adenovirus 12 and transformed rat cells. Nature 1983; 305: 771-5.
127. Friedman DJ, Ricciardi RP. Adenovirus type 12 E1A gene represses accumulation of MHC class 1 mRNAs at the level of transcription. Virology 1988; 165: 303-5.
128. Shemesh J, Rotem-Yehudar R, Ehrlich R. Transcriptional and post transcriptional regulation of class 1 major histocompatibility complex genes following transformation with human adenovirus. J. Virol. 1991; 65: 5544-48.
129. Ozawa K, Hagiwara H, Tang X et al. Negative regulation of the gene for H-2Kb class 1 antigen by adenovirus 12-E1A is mediated by a CAA repeated element. J. Biol. Chem. 1993; 268: 27 258-68.
130. Vasavada R, Eager KB, Barbanti-Brodano G, Caputo A, Ricciardi RP. Adenovirus type 12 early region 1A proteins repress class 1 HLA expression in transformed human cells. Proc. Natl Acad. Sci. USA 1986; 83: 5257-61.
131. Bernards R, Schrier PI, Houweling A, Bos JL, Van der Eb AJ. Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity. Nature 1983; 305: 776-9.
132. Schouten GJ, Van der Eb AJ, Zantema A. Downregulation of MHC class I expression due to interference with p105-NFkB1 processing by Ad12E1A. EMBO J. 1995; 14: 1498-1507.
133. Fan C-M, Maniatis T. Generation of p50 subunit of NF-kB by processing of p105 through an ATP-dependent pathway. Nature 1991; 354: 395-8.
134. Blank V, Kourilsky P, Israël A. Cytoplasmic retention, DNA binding and processing of the NK-kB p50 precursor are controlled by a small region in its C-terminus. EMBO J. 1991; 10: 4159-67.
135. Rotem-Yehudar R, Winograd S, Sela S, Coligan JE, Ehrlich R. Downregulation of peptide transporter genes in cell lines transformed with the highly oncogenic adenovirus 12. J. Exp. Med. 1994; 180: 477-88.
136. Rawle FC, Knowles BB, Riccardi RP et al. Specificity of the mouse cytotoxic T lyphocyte response to adenovirus 5. E1A is immunodominant in H-2B, but not in H-2D or H-2K mice. J. Immunol. 1991; 146: 3977-84.
137. Zhang X, Bellett AJD, Tha Hla R, Braithwaite AW, Müllbacher A. Adenovirus type 5 E3 gene products interfere with the expression of the cytolytic T cell immunodominant E1a antigen. Virology 1991; 180: 199-206.
138. Spriggs MK. One step ahead of the game: viral immunomodulatory molecules. Annu. Rev. Immunol. 1966; 14: 101-30.